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Abstract
Aim
To summarise and quantify the effect of tobacco smoking on the risk of developing commu-
nity acquired pneumonia (CAP) in adults.
Methods
We systematically searched MEDLINE, Embase, CINAHL, PsychINFO and Web of Sci-
ence, from inception to October 2017, to identify case-control and cohort studies and
reported in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) checklist. The review protocol was registered with the PROS-
PERO database (CRD42018093943). Study quality was assessed by the Newcastle-
Ottawa Scale. Pooled odds ratios (ORs) or hazard ratios (HRs) were estimated using a ran-
dom-effects model.
Results
Of 647 studies identified, 27 studies were included (n = 460,592 participants) in the system-
atic review. Most of the included studies were of moderate quality with a median score of six
(IQR 6–7). Meta-analysis showed that current smokers (pooled OR 2.17, 95% CI 1.70–
2.76, n = 13 studies; pooled HR 1.52, 95% CI 1.13–2.04, n = 7 studies) and ex-smokers
(pooled OR 1.49, 95% CI 1.26–1.75, n = 8 studies; pooled HR 1.18, 95% CI 0.91–1.52, n =
6 studies) were more likely to develop CAP compared to never smokers. Although the asso-
ciation between passive smoking and risk of CAP in adults of all ages was not statistically
significant (pooled OR 1.13, 95% CI 0.94–1.36, n = 5 studies), passive smoking in adults
aged�65 years was associated with a 64% increased risk of CAP (pooled OR 1.64; 95% CI
1.17–2.30, n = 2 studies). Dose-response analyses of data from five studies revealed a sig-
nificant trend; current smokers who smoked higher amount of tobacco had a higher risk of
CAP.
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Conclusion
Tobacco smoke exposure is significantly associated with the development of CAP in current
smokers and ex-smokers. Adults aged > 65 years who are passive smokers are also at
higher risk of CAP. For current smokers, a significant dose-response relationship is evident.
Introduction
Community acquired pneumonia (CAP) is a common communicable disease with an esti-
mated annual age-adjusted incidence of 465–649 patients hospitalised with CAP per 100,000
population in the United States. [1,2] In 2016, lower respiratory tract infections (LRTIs)
including CAP were reported as the ‘most deadly communicable disease’ worldwide, causing
three million deaths and were the second commonest reason for years of life lost after ischae-
mic heart disease.[3,4]
Tobacco smoking is a major cause of morbidity and mortality in high income countries
and is an important risk factor for CAP.[5] Tobacco smoking impairs mucociliary clearance
by causing an increase in mucous production and number of abnormal cilia alongside reduc-
tion of ciliary beat frequency.[6] Piatti et al. found that tobacco smoking modifies buccal epi-
thelial surfaces which causes increased pneumococcal adherence compared to never smokers.
[7] Greater bacterial adherence may lead to greater oropharyngeal colonisation and hence a
greater risk of developing CAP. Exposure to low levels of tobacco smoking or passive smoking
has also been shown to be associated with modification in the lung cell biology similar to that
seen in current smokers. [8,9]
A recent systematic review of risk factors for CAP in adults published by Almirall et al.
found that tobacco smoking was a significant risk factor for CAP compared to never smokers,
however the strength of association was not quantified.[10] Passive smoking has been shown
to increase the risk of lower respiratory tract infections (LRTIs) in children whose parents
smoke[11], yet there has been no systematic review to summarise the risk for developing CAP
in adults.
The aim of this systematic review and meta-analyses was to summarise the available evi-
dence regarding the effect of tobacco smoking and passive smoke exposure on the risk of
developing CAP in adults, to determine the strength of the association and to examine whether
there is a ‘dose-response’ association between amount of tobacco smoked and the risk of devel-
oping CAP.
Methods
This systematic review was conducted using a predefined protocol which was registered with
PROSPERO database (CRD42018093943) and reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.
Search strategy and study selection
The search strategy was designed to find published studies. Comprehensive searches of the fol-
lowing biomedical electronic databases were conducted: MEDLINE, Embase, CINAHL, Psy-
cINFO and Web of Science from the commencement of these databases to October 2017. The
search strategy included subject headings and keywords related to “community acquired pneu-
monia” and “smoking”. Search keywords were determined from the Cochrane review group
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terms for tobacco.[12] Details of the search strategy for each database are found in S1 File. The
reference list of all included studies were screened for inclusion.
This review included observational studies; prospective and retrospective cohort studies
and case-control studies. Cross-sectional studies were excluded. Studies published in all lan-
guages were considered and no date restrictions were placed on searches. Studies comprising
adults aged 15 years and above with either a clinical or radiology-confirmed diagnosis of CAP
were included. Studies comprising patients with hospital acquired pneumonia, aspiration
pneumonia, active pulmonary TB and post-obstructive pneumonia secondary to thoracic
malignancy were excluded.
Two authors (VB, AH, RM or TM) independently screened titles and abstracts using Covi-
dence software[13] and subsequently reviewed full-texts of retrieved studies for eligibility. Dis-
agreement was resolved by discussion and consensus, involving a third reviewer (TM or WSL)
where necessary.
Data extraction and assessment of methodological quality
Two authors (VB, RM or TM) independently extracted all data for studies in English whilst
data from non-English studies were extracted by a single reviewer (TL, LB, MOB or KN) who
was literate in that particular language using a standardised form. Any disagreements that
arose between reviewers were resolved through discussion, or with a third reviewer (TM)
when required. Information on study population, study design, exposure of interest (tobacco
smoking) including different exposure categories (e.g. never, ever, ex-, current, ‘not current’
and passive smokers), outcome (CAP) and the adjusted/ unadjusted effect size (either odds
ratios (ORs) or hazard ratios (HRs)) were collected.
Methodological quality was assessed using the Newcastle-Ottawa Quality Assessment Scale
[14] for either cohort or case-control studies depending on individual study design. This scale
is based on three broad categories; (1) selection of the study sample (four points), (2) compara-
bility of the sample groups (two points) and (3) ascertainment of exposure/ outcome (three
points). Thus, studies were scored out of a total of nine points. Scores were chosen a priori to
indicate different levels of methodological quality (0–3: low quality, 4–6: moderate quality,
7–9: high quality)
Data synthesis
We reviewed the extracted results to assess if adequate similarity existed for study outcomes to
conduct a random-effects meta-analysis using Stata/ SE 15.1 (StataCorp. 2017). Meta-analysis
was performed using 26 studies comparing current (selecting the highest amount of tobacco
smoked for current smokers where there was more than one category), ever, ex- and passive
versus never smokers in addition to comparing current versus ‘not current’ smokers. We
assessed publication bias visually using a funnel plot for the association between current smok-
ing and the risk of CAP given that there were more than 10 studies included in this meta-anal-
ysis. We summarised studies with pooled ORs and HRs separately with 95% confidence
intervals. Measures of effect adjusted for confounders (age and sex were a priori confounders)
were used in preference to crude measures of effect. The I2 statistic was used to assist with
assessment of heterogeneity between studies. We performed sensitivity analysis excluding
studies with only specific medical conditions (we use the term ‘selected clinical populations’ in
the rest of this paper) so that the data would be representative of the general population. In
order to explore ascertainment bias, we compared the effect size in primary care versus sec-
ondary care settings. We plotted the log ratio for each category within a study (assuming a lin-
ear relationship) and estimated the dose-response regression coefficient to determine the
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dose-response association between the dose of current smoking and the risk of developing
CAP.
Results
The search strategy initially identified 647 studies, from which 56 full-text articles (including
five non-English studies; French, Chinese, German and Spanish) were reviewed (Fig 1).
Twenty five English studies and two non-English studies were included in the systematic
review (n = 460,592 participants) (S1 Table). The most common reason for exclusion was lack
of documented relevant outcome data (n = 17/56).
Characteristics of included studies
Of 27 included studies, there were 13 cohort studies and 14 case-control studies. All except
two studies included both genders; two studies only included men.[15,16] Five studies had
selected clinical populations including patients with human immunodeficiency virus (HIV)
[17], selected HIV-related medical conditions[16], minor thoracic injury[18] and chronic
obstructive pulmonary disease (COPD)[19,20]. One study reported an outbreak of Legion-
naires’ disease and included participants who visited an aquarium.[21] Six studies were con-
ducted in primary care, nine in hospitals, four in mixed settings, six in community settings
and two not specified (S1 Table). The definition of CAP was based on radiological confirma-
tion in 16 studies, diagnostic coding in five studies (four studies used ICD-9 codes and one
Fig 1. PRISMA flow diagram for study selection.
https://doi.org/10.1371/journal.pone.0220204.g001
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study used Clinical Practice Research Datalink read codes) and clinical criteria in five studies;
one study did not report the way CAP was defined.
Risk of bias
Most of the studies (n = 16 studies) included were of moderate quality with a median quality
score of six (IQR 6–7) (S2 Table). Using the a priori methodological quality scores, we judged
ten studies to be of high quality and one study of low quality. Twenty-four studies (88.9%) had
clear definitions of CAP either using independent blind assessment of chest radiographs, med-
ical records or record linkage (e.g. ICD codes) and 23 studies (85.2%) adjusted for confound-
ers. Thirteen (92.9%) out of all case-control studies scored low as a result of lack of non-
response rate reporting and poor smoking status ascertainment (obtained information from
interview that was not blinded to case/ control status or were self-reported). In contrast, over
half of the cohort studies (n = 8 studies, 61.5%) scored well for smoking status ascertainment;
either from a secure medical record or structured interview with the participant. The quality
for some of the cohort studies dropped due to a combination of lacking a truly representative
exposed cohort (n = 8 studies, 61.5%), not demonstrating that CAP was not present at the start
of the study (n = 8 studies, 61.5%) and not having a statement about loss to follow-up (n = 9
studies, 69.2%).
Smoking status
The most commonly used definitions of smoking status are detailed in Table 1. Most studies
state the smoking categories without providing detailed definition for respective categories; we
have used the definition for each category from the Glossary detailed in the Adult Tobacco
Use Information by the Centers for Disease Control and Prevention (Table 1).[22]
Four studies quantified tobacco smoking by documenting pack-years[23,24] and reporting
qualitative descriptions from light through to heavy smoking.[16,25] ‘Not current’ smoking
category which could include never, ever and ex-smokers was used in two studies. The propor-
tion of current smokers with CAP was higher in secondary care (31–79%) compared to pri-
mary care (21–27.3%).
Meta-analyses
Meta-analysis of 13 studies showed that current smokers were more than twice at risk of devel-
oping CAP than never smokers (pooled OR 2.17, 95% CI 1.70–2.76, I2 = 75%) (Fig 2). Sensitiv-
ity analysis excluding studies which were not representative of the general population (two
studies with selected clinical populations[16,18] and one study which recruited participants
who visited an aquarium[21]) found a marginally lower effect (pooled OR 1.91, 95% CI 1.54–
Table 1. Smoking categories used in included studies.
Smoking
categories
Definition[22] Synonyms used in included
studies
Number of studies
Never Never smoked or lifetime smoking history of <100 cigarettes Non 27
Ever Lifetime smoking history of�100 cigarettes ‘Current/ past’
‘Current/ ex’
4
Ex Lifetime smoking history of�100 cigarettes and stopped smoking at the time of the
study
Former, past 15
Current Lifetime smoking history of�100 cigarettes and currently smokes at the time of the
study
Active 18
Passive Never smokers who are exposed to environmental cigarette smoke Exposure to second-hand smoke 6
https://doi.org/10.1371/journal.pone.0220204.t001
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2.38, I2 = 70.8%, n = 10 studies) (Fig 2). There was no evidence of publication bias identified
from the funnel plot for the association between current smoking and the risk of CAP (Fig 3).
Studies that reported hazards ratios found that current smokers were 53% more likely to
develop CAP than never smokers (pooled HR 1.52, 95% CI 1.13–2.04, I2 = 89.5%, n = 7 stud-
ies) (Fig 4). The risk increased slightly when three studies with selected clinical populations
were removed (pooled HR 1.72, 95% CI 1.43–2.07, I2 = 19.3%) (Fig 4). Compared to ‘not cur-
rent’ smokers, meta-analysis of two studies revealed that current smokers were almost three
times at risk of developing CAP (pooled OR 2.75, 95% CI 1.29–5.88, I2 = 58.3%, n = 2 studies)
(Fig 5). There was only one study which compared current smokers to ‘not current’ smokers
and reported hazards ratio (HR 1.31, 95% CI 1.17–1.46), hence this study was not included in
the meta-analysis. [26] Meta-analysis of four studies showed that ever smokers were more than
twice at risk of developing CAP than never smokers (pooled OR 2.31, 95% CI 1.99–2.69, I2 =
0%, n = 4 studies) (Fig 6).
Ex-smokers were 49% more likely to develop CAP than never smokers (pooled OR 1.49,
95% CI 1.26–1.75, I2 = 13.3%, n = 8 studies) (Fig 7). Sensitivity analysis excluding two studies
which were not representative of the general population found a similar result (pooled OR
1.51, 95% CI 1.24–1.84, I2 = 29.9%, n = 6 studies) (Fig 7). Studies reporting hazard ratios had a
high level of heterogeneity and did not find a significant effect between ex-smokers and the
risk of developing CAP (All eligible studies: pooled HR 1.18, 95% CI 0.91–1.52, I2 = 85.4%,
n = 6 studies and sensitivity analysis: pooled HR 1.25, 95% CI 0.88–1.78, I2 = 75.3%, n = 2 stud-
ies) (Fig 8).
For studies conducted only within a primary care setting, the effect of current smoking on
the risk of developing CAP was not statistically significant (pooled OR 1.14, 95% CI 0.72–1.82,
I2 = 55.1%, n = 2 studies and pooled HR 1.21, 95% CI 0.68–2.15, I2 = 92.8%, n = 2 studies)
whereas for studies conducted in a secondary care setting, current smoking was significantly
Fig 2. Meta-analysis of risk of community acquired pneumonia in current smokers relative to never smokers
(Odds Ratio). � Study by Baik et al. had relevant data subdivided by gender, therefore data from this study were
included as two separate entities (i.e. men and women). Grey box = effect estimates from single studies.
Diamond = pooled result with confidence interval. Vertical line at ‘1’ on the x-axis is the line of no effect. Weight (in
%) = influence an individual study had on the pooled result.
https://doi.org/10.1371/journal.pone.0220204.g002
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associated with CAP compared to never smokers (pooled OR 1.95, 95% CI 1.45–2.62, I2 =
0.0%, n = 4 studies and HR 1.58, 95% CI 1.32–1.89, n = 1 study).
Passive smoking was associated with a 13% increased risk of developing CAP compared to
those who were not exposed to passive smoking, however this result was not statistically signif-
icant (pooled OR 1.13, 95% CI 0.94–1.36, I2 = 26.8%, n = 5 studies). In a sensitivity analysis of
Fig 3. Funnel plot for the association between current smoking and the risk of developing CAP.
https://doi.org/10.1371/journal.pone.0220204.g003
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those� 65 years old, passive smoking was associated with 64% increased risk of CAP (pooled
OR 1.64; 95% CI 1.17–2.30, I2 = 0%, n = 2 studies).
Dose-response trend: Narrative review
Five studies had information on the dose-response association between amount of smoking
and the risk of developing CAP. We performed dose-response analyses using the data arising
from these five studies (Table 2) although a meta-analysis was not possible due to variations in
the method of quantification of smoking exposure across studies. Significant dose-response
relationships were found in all studies; there were two linear[23,27] and three non-linear
Fig 4. Meta-analysis of incidence of community acquired pneumonia in current smokers relative to never smokers (Hazards Ratio). Grey box = effect estimates
from single studies. Diamond = pooled result with confidence interval. Vertical line at ‘1’ on the x-axis is the line of no effect. Weight (in %) = influence an individual
study had on the pooled result.
https://doi.org/10.1371/journal.pone.0220204.g004
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[16,25,28] associations with the effect in one study being mainly driven by results from the
highest two categories (Table 2).[25]
Discussion
To our knowledge, this is the first study to quantify the effect of tobacco smoking on the risk
of developing CAP through a meta-analysis. Our study revealed robust evidence that current
and ex-smokers are significantly at higher risk of developing CAP whilst passive tobacco
smoke exposure had a significant effect only in those aged� 65. The strongest associations
were evident in studies conducted in secondary care. In addition, a dose-response trend with
higher risk of CAP amongst current smokers who smoke higher amounts of tobacco was
noted.
Current smoking has been associated with a wide spectrum of infectious diseases including
bacterial pathogens (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningiti-
dis, Staphylococcus aureus, Legionella pneumophila, Mycobacterium tuberculosis) and viral
pathogens (influenza, rhinovirus, HIV).[29–34] Whether smoking increases the risk of infec-
tion from different respiratory pathogens by the same degree could not been fully examined in
this systematic review due to lack of relevant data in the included studies.
Fig 5. Meta-analysis of risk of community acquired pneumonia in current smokers relative to ’not current’ smokers (Odds Ratio). Grey box = effect
estimates from single studies. Diamond = pooled result with confidence interval. Vertical line at ‘1’ on the x-axis is the line of no effect. Weight (in %) = influence
an individual study had on the pooled result.
https://doi.org/10.1371/journal.pone.0220204.g005
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We quantified the risk of developing CAP in current smokers to be similar to the associa-
tion of smoking with asthma (RR 1.61; 95% CI, 1.07–2.42), idiopathic pulmonary fibrosis (OR
1.58; 95% CI 1.27–1.97), obstructive sleep apnoea (RR 1.97; 95% CI 1.02–3.82), stroke (HR
1.58; 95% CI 1.40–1.78) and acute coronary syndrome (HR 1.98; 95% CI 1.75–2.25) though
lower than that of developing lung cancer (HR 13.1; 95% CI 9.90–17.3) and COPD (RR 4.01;
95% CI, 3.18–5.05).[35–38]
Our findings advance the descriptive presentation in two previous systematic reviews
which reported that smoking is an independent modifiable risk factor for developing CAP
alongside other lifestyle factors including alcohol abuse, low body mass index, having regular
contact with children and poor dental hygiene.[10,39] Smoking also has an indirect effect on
the risk of CAP as it is associated with COPD and poor dental health which are themselves
independent risk factors for developing CAP. [24,28,35,40,41] This indirect effect has not been
quantified.
In a cohort of immunocompetent adults aged 18–64 years old with invasive pneumococcal
disease (IPD), Nuorti et al. showed that passive smoking was an independent risk factor (OR
2.5; 95% CI 1.2–5.1) with increased risk observed with longer duration of passive smoke expo-
sure.[42] Although passive smoking was not associated with increased risk of CAP in adults of
Fig 6. Meta-analysis of risk of community acquired pneumonia in current smokers relative to ’ever’ smokers (Odds Ratio). Grey box = effect estimates from
single studies. Diamond = pooled result with confidence interval. Vertical line at ‘1’ on the x-axis is the line of no effect. Weight (in %) = influence an individual
study had on the pooled result.
https://doi.org/10.1371/journal.pone.0220204.g006
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all ages, it is noteworthy that meta-analysis of two studies showed an increased risk in those
�65 years; one study recruited patients from primary care (exposed to passive smoke at home)
and the other following hospitalisation for CAP (exposed to any passive smoke). A combina-
tion of host factors such as comorbidities that accompany advanced age, polypharmacy and
immune senescence as well as social factors including poor nutrition and crowding or long-
term residential care may contribute to the increased risk of infection seen in the elderly. [43]
We were able to perform dose-response analyses using data from five studies. Our analyses
confirmed that higher levels of smoking exposure are associated with higher risks of
Fig 7. Meta-analysis of risk of community acquired pneumonia in ex-smokers relative to never smokers (Odds Ratio). Grey box = effect estimates from single
studies. Diamond = pooled result with confidence interval. Vertical line at ‘1’ on the x-axis is the line of no effect. Weight (in %) = influence an individual study had on
the pooled result.
https://doi.org/10.1371/journal.pone.0220204.g007
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developing CAP. This is consistent with data from IPD where a linear dose-response relation-
ship with number of cigarettes smoked daily has been reported.[44] In the two studies that
combined current and ex-smokers in their analyses, the dose-response relationship between
amount of smoking and risk of CAP was linear, whereas in the remaining three studies which
had current smokers, the relationship was non-linear. An individual patient data analysis
would be required to determine how the differences in the categorisation of smoking status
influence the linearity of the dose-response relationship.
Tobacco smoking and infection: Immune mechanisms
In addition to structural mechanisms mentioned in the ‘Introduction’ section,[6,7,45] smok-
ing may increase the risk of systemic infections by causing changes in cellular and humoral
immune system function.[46] Smoking impairs polymorphonuclear leukocyte function which
Fig 8. Meta-analysis of incidence of community acquired pneumonia in ex-smokers relative to never smokers (Hazards Ratio). Grey box = effect estimates from
single studies. Diamond = pooled result with confidence interval. Vertical line at ‘1’ on the x-axis is the line of no effect. Weight (in %) = influence an individual study
had on the pooled result.
https://doi.org/10.1371/journal.pone.0220204.g008
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plays a significant role in the host defence against bacterial infection (depressed neutrophil
migration and leukocyte chemotaxis),[47,48] decreases CD4+ T cell counts which results in
reduction of B cells that secrete antibodies (thus lowering serum immunoglobulin levels by
approximately 10%),[49–53] increases CD8+ T cell counts,[54] and decreases secretion of pro-
inflammatory cytokines such as IL-1 and IL-6.[55,56] Nicotine from tobacco smoking can also
suppress natural killer (NK) cell activity; NK cells are usually activated as part of the early
immune surveillance response against viral infections.[57]
Effect of tobacco smoking cessation
The only study included in this review that reported time from smoking cessation to develop-
ment of CAP was a population-based case-control study by Almirall et al. which reported that
the risk of CAP reduced by 50% (OR) after five years of smoking cessation.[23] In a study of
invasive pneumococcal disease (IPD), the risk of IPD in ex-smokers reduced by 14% annually
and to that of never smokers about 13 years after smoking cessation.[44] These observations
alongside the results from this meta-analysis support the notion that ex-smokers have a lower
risk of CAP than current smokers and that this risk decreases with duration of smoking
cessation.
Why ex-smokers remain at risk of CAP is unclear. Bacterial adherence is crucial in the path-
ogenesis of infection. Ex-smokers have been shown to have increased in vitro adherence of
Streptococcus pneumoniae to buccal epithelial cells for up to three years after smoking cessation
which may contribute to the increased risk of CAP.[45] In terms of alterations to immune
function, reports have been mixed; one study found a significantly lower proportion of NK
Table 2. Dose-response relationship between amount of smoking and risk of developing CAP. Trend (OR) of 1.xy means xy% increase of risk of CAP per increase in
category documented in the ‘Quantification of smoking exposure’ column.
Study Smoking status Quantification of smoking exposure Trend (OR) p value Association
Almirall
1999
Current & ex-
smokers
Pack-years
• 0
• 5–16.4
• 16.5–38
• >38
1.37, 95% CI
1.17–1.61
<0.001 Linear
Almirall
2008
Current & ex-
smokers
Packs of cigarettes smoked daily x 365 x
years smoked$
• 0
• 1–150
• 151–300
• >300
1.27, 95% CI
1.17–1.38
<0.001 Linear
Almirall
1999
Current smokers Cigarettes smoked daily
• 0
• 1–9
• 10–20
• >20
1.30, 95% CI
1.02–1.67
0.037 Non-linear
Farr 2000 Current smokers Cigarettes smoked daily x years smoked
• 0
• 1–225
• 226–578
• 579+
1.52, 95% CI
1.30–1.78
<0.001 Non-linear; effect mainly in the highest two categories of
smoking (in bold)
Conley
1996
Current smokers Packets of cigarettes daily
• � half (‘light’)
• half to <2 (‘moderate’)
• >2 (‘heavy’)
1.51, 95% CI
1.10–2.08
0.011 Non-linear
$This formula was clarified directly by personal correspondence with study author.
https://doi.org/10.1371/journal.pone.0220204.t002
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cells in ex-smokers who had stopped smoking for over 20 years compared to never smokers
(mean duration since smoking cessation of 10.7 years)[58], whereas in another study of 10 ex-
smokers where duration since smoking cessation ranged from six weeks to 10 years (mean = 4
years), NK cell activity was comparable to that of never smokers.[59] In heavy smokers (�50
pack-years), smoking cessation for six weeks has been associated with a return of the CD4/
CD8 ratio to normal.[60], Therefore, although some of the immune related effects of smoking
may be relatively rapidly reversed upon stopping smoking, other effects may be more pro-
longed, or possibly irreversible.
Strengths and limitations
This review comprehensively summarises the current body of knowledge regarding the effect
of tobacco smoking on the risk of developing CAP and was reported in accordance with
PRISMA checklist (S2 File). Eligibility criteria were strictly applied to ensure identified studies
only included patients with CAP, hence excluding hospital-acquired pneumonia, aspiration
pneumonia, active pulmonary TB and post-obstructive pneumonia secondary to thoracic
malignancy. Overall, included studies were of moderate quality and no language restrictions
were applied. The statistical heterogeneity for the meta-analysis varied across the different
analysis, ranging from low (<25%) to high (>75%) level and did not change significantly in
the sensitivity analysis.
An important limitation was the various ways in which smoking status was defined and
smoking ‘dose’ quantified. For instance, the lack of distinction of ‘ever’ and ‘not current’ smok-
ers from ‘ex-smokers’ precluded seven studies from the meta-analysis involving ex-smokers.
Definitions of CAP also varied, though to a lesser extent. Studies that did not adopt the ‘gold
standard’ of radiologically confirmed CAP (n = 10 studies) may have captured some cases of
LRTI or acute bronchitis instead. Non-pneumonic respiratory tract infections (RTIs) are gen-
erally considered to be more likely to be caused by viral pathogens instead of bacterial patho-
gens.[61] However, there are no comparative data to suggest a differential effect of smoking on
the occurrence of viral versus bacterial RTIs. Therefore, inclusion of these studies is not
expected to exert a major bias on pooled results.
Implications
This review provides good evidence to support recommendations for smoking cessation as
well as avoidance of passive exposure to tobacco smoke, particularly in persons at high risk of
developing pneumonia. Patients who recover from an episode of CAP are recognised to be at
risk of recurrent CAP[62–64]. Therefore hospitalisation with CAP provides a valuable ‘teach-
able moment’ when smoking cessation should be promoted. [65–67]
Further research is warranted to establish why and for how long ex-smokers continue to be
at higher risk of developing CAP following smoking cessation, compared to those who have
never smoked. For future studies, a more standardised approach to reporting pack-years of
smoking instead of qualitative descriptions with variable definitions would facilitate compari-
sons and synthesis of data.
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